ZoeNCure's Liver Cancer ADC Bet Draws $2.4M Seed From Tyagi Family

ZoeNCure Therapeutics, a Delhi-based oncology biotechnology startup developing high-potency targeted cancer therapies, has closed a Rs 20 crore (approximately $2.4 million) seed financing round, the company announced on October 3, 2026.

The round was led by the Tyagi Family, high-net-worth individuals based in Gurugram, with Shyambir Tyagi and Manoj Tyagi heading the investment. Angel co-investors also participated.

This is the second time the Tyagi Family has backed the company. They previously provided a Rs 2.5 crore pre-seed investment to fund ZoeNCure's foundational operations. With the follow-on capital, the company's total equity raised now stands at Rs 22.5 crore.

The seed proceeds are earmarked for a specific milestone: moving ZoeNCure's lead Antibody Drug Conjugate (ADC) candidate toward first-in-human Phase 1 clinical studies in severe liver and gastrointestinal cancers, specifically hepatocellular carcinoma (HCC). The funding will support preclinical studies, CMC scale-up, and regulatory submissions to India's Central Drugs Standard Control Organisation (CDSCO).

The round is small by global oncology standards, but it is structured around a capital-efficient path — a single lead ADC asset, an Indian regulatory filing, and a defined preclinical-to-IND window. That framing is increasingly common among early-stage Indian biotechs that want to reach a clinical inflection point without a large cross-border syndicate.

It also puts the company squarely in one of biopharma's most active modality races. ADCs have become a focal point of dealmaking and clinical investment in recent years because they pair a tumour-targeting antibody with a cytotoxic payload, an approach that can widen the therapeutic window over conventional chemotherapy. Liver and gastrointestinal cancers, including HCC, remain areas of high unmet need, particularly in Asia.

For ZoeNCure, the immediate test is execution rather than scale. The seed capital must carry the lead candidate through preclinical validation, chemistry, manufacturing and controls scale-up, and a CDSCO submission. CMC work in particular tends to absorb both time and money for ADC developers, since linking a payload to an antibody reliably at commercial scale is a manufacturing problem as much as a scientific one.

The Tyagi Family's decision to double down rather than bring in a new institutional lead is notable for a seed-stage biotech. It keeps the cap table concentrated and the shareholder base domestic, while leaving room for a larger syndicate to come in around a clinical readout. Whether that syndicate materialises will depend on how quickly ZoeNCure can convert Rs 20 crore of runway into a Phase 1-ready asset.